Perseris

Elderly with dementia-related psychosis (not approved use); increased risk of death or cerebrovascular events (eg, stroke, TIA). Discontinue if neuroleptic malignant syndrome (NMS) occurs. Consider discontinuing if tardive dyskinesia occurs. Monitor for metabolic changes that may increase cardio- or cerebrovascular risk (eg, hyperglycemia, dyslipidemia, weight gain). Diabetes risk factors (eg, obesity, family history); obtain baseline and periodic fasting blood glucose. Pre-existing low WBCs or history of leukopenia/neutropenia: monitor CBCs during 1^st few months of therapy; discontinue if WBCs decline. Known cardio- or cerebrovascular disease, and other conditions (eg, dehydration, hypovolemia): monitor orthostatic vital signs and consider dose reduction if hypotension occurs. Perform fall risk assessments when initiating and recurrently on long-term therapy. History of seizures or conditions that can lower the seizure threshold. Risk of aspiration pneumonia. Exposure to extreme temperatures. Re-evaluate periodically. Renal or hepatic impairment. Neonates: risk of extrapyramidal and/or withdrawal symptoms post delivery (due to exposure during 3^rd-trimester pregnancy). Pregnancy. Nursing mothers: monitor infants.